Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05212272 · ClinicalTrials.gov registry record · NA
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
A NA study of High Grade Glioma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05212272: Recruiting NA study of High Grade Glioma, sponsored by Wake Forest University Health Sciences.
NCT05212272 is a NA study of High Grade Glioma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 16 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05212272, a NA study of High Grade Glioma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.
Primary Outcome
Feasibility is defined as 70% of patients who complete two PET scans. This proportion and its 95% confidence interval will be calculated at 4 months
Conditions Studied
Interventions
- PROCEDURE PET-MRI Brain Scan
- DIAGNOSTIC_TEST Blood draw
- BEHAVIORAL Memory testing
- PROCEDURE Optional lumbar puncture for cerebrospinal fluid collection
Study Locations (1)
North Carolina
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-09-02 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT05212272 shows while recruiting
NCT05212272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with High Grade Glioma appearing as the primary indexed condition, and to 4 interventions - of which PET-MRI Brain Scan is the first listed.
NCT05212272 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05212272 about?
NCT05212272 is a clinical study titled "MRI in High-Grade Glioma Patients Undergoing Chemoradiation". The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET...
What is the current status of trial NCT05212272?
This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2022-09-02. Estimated completion is 2026-12.
What conditions does trial NCT05212272 study?
This clinical trial studies the following conditions: High Grade Glioma.
What interventions are being tested in trial NCT05212272?
The interventions under investigation include: PET-MRI Brain Scan (PROCEDURE), Blood draw (DIAGNOSTIC_TEST), Memory testing (BEHAVIORAL), Optional lumbar puncture for cerebrospinal fluid collection (PROCEDURE).
Who is sponsoring clinical trial NCT05212272?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05212272 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05212272's enrollment target sits among peer trials
16 36th of 42 higher than 6 of 42 other High Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
RECRUITING · NA
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RECRUITING · Phase 2
-
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI